Skip to main content
2024 BMES Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

High School Student with a Traditionally Underrepresented Background

HS Poster

Poster 106 - MG53 Inhibits Periosteum-Derived Progenitor Cell Differentiation Into Osteoblasts

Saturday, October 26, 2024
10:00 AM - 12:00 PM EST
Location: Exhibit Hall E, F & G

    Presenting Author(s)

  • Jessica Guan (she/her/hers)

    Student
    Lafayette High School
    Wildwood, Missouri, United States

    • Co-Author(s)

  • YH

    Yonghua He

    Research Specialist
    Washington University in St. Louis, United States

  • AL

    Aiwu Lu

    Lab Manager
    Washington University in St. Louis, United States

    • Primary Investigator(s)

  • Jie Shen, PhD

    Associate Professor
    Washington University in St. Louis, United States


Introduction: MG53, a TRIM-family protein with therapeutic potential in regenerative medicine, has been shown to facilitate cell membrane repair, reduce inflammation, and prevent stem cell apoptosis in various tissues, including skeletal muscle, cardiac muscle, and bone marrow. This study explores the impact of MG53 on periosteum-derived progenitor cell (PDPC) differentiation to assess the protein’s suitability for promoting fracture repair.

Materials and

Methods: This study comprises a controlled experiment comparing gene expression among 2-week old mouse pup PDPCs treated with 2, 5, and 10 μg/mL MG53 in differentiation medium against untreated cells. The osteogenic and adipogenic lineages were seeded onto gelatin-coated plates and the chondrogenic lineage was cultured as pellets. mRNA was harvested at 14 and 21 days, while remaining cells were stained at 21 days. We employed staining and qPCR with SYBR Green to quantify differentiation-related gene expression.

Results, Conclusions, and Discussions: Dosage comparison via qPCR demonstrated that PDPCs treated with 2 μg/mL MG53 in MEM-ɑ showed PPARγ downregulation while maintaining SOX9 and Sp7/Osx expression. All three genes showed reduced expression with the 5 and 10 μg/mL treatments. Alizarin Red S staining of 2 μg/mL-treated osteogenic cells showed notably less calcium matrix deposition compared to controls. Additionally, qPCR of the treated osteogenic lineage demonstrated lower aggrecan expression.
MG53 at 2 μg/mL in vitro inhibits PDPC differentiation into osteoblasts. This dose for PDPCs is unsuitable for bone fracture repair. Further research is needed to elucidate the effects of a wider dose range and clarify the detailed interaction mechanisms between MG53 and PDPCs.

Acknowledgements (Optional):

References (Optional):